A Phase 2 interventional study of Cyclophosphamide and Bortezomib in Multiple Myeloma, sponsored by Janssen-Cilag G.m.b.H. Completed at 35 sites in Germany. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2014-11-21.
Sponsored by Janssen-Cilag G.m.b.H (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 171 studies testing cyclophosphamide in Multiple Myeloma — 15 open to participants now, 27 under way, 1 of them phase 3. Cyclophosphamide · Multiple Myeloma.
Among the 171 studies testing cyclophosphamide in Multiple Myeloma, this one is the 6th largest by enrollment of the 167 interventional ones that give a count, is one of 10 that started in 2006, is one of 92 in phase 2, and was the 56th registered.
3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.
Browse Multiple Myeloma studies →15 of the 171 studies testing cyclophosphamide in Multiple Myeloma are open now, in 4 countries. Recruiting first, the newest first:
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
Washington University School of Medicine · Sites in United States
Ages 18+
Northside Hospital, Inc. · Sites in United States
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
By country, each count listing its studies:
Cyclophosphamide: first FDA approval 1959 (CYTOXAN). What it is approved for, and how studies give it, is on its page →
Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
171 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 55 · Phase 2 116 · Phase 3 16
First in 1988; this study’s year is marked. 10 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 401 is above the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.
Median enrollment 41 across the 167 interventional studies. Of the 119 that completed or were terminated, 68 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 171 have an industry lead sponsor. The 10 most frequent:
This study is registered under Janssen-Cilag G.m.b.H, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen-Cilag G.m.b.H is the lead sponsor of 11 studies on the registry; 1 is open to participants now.
126 studies in Multiple Myeloma by Johnson & Johnson: 13 open now, 33 under way, 12 of them phase 3. Of 82 finished, 33 (40%) have results posted.
Among the 126 studies in Multiple Myeloma by Johnson & Johnson, this one is the 18th largest by enrollment of the 100 interventional ones that give a count, is one of 11 that started in 2006, is one of 32 in phase 2, and was the 26th registered.
Johnson & Johnson’s Multiple Myeloma studies by the year they started, since 1995.
8 of the studies testing cyclophosphamide in Multiple Myeloma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05909059Northside Hospital, Inc.CAR T-cell Therapy in Patients With Renal Dysfunction | 2026-12-31 |
| NCT04166565Stichting European Myeloma NetworkDaratumumab Combined With Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting With Extramedullary Disease | 2027-03 |
| NCT06623630Washington University School of MedicineLymphodepleting Total Body Irradiation (TBI) Plus Cyclophosphamide Prior to Ciltacabtagene Autoleucel (Carvykti; Cilta-cel) for Multiple Myeloma (MM) Patients With Impaired Renal Function | 2027-06-30 |
| NCT05909826Dong-A University HospitalCarfilzomib, Oral Cyclophosphamide, and Dexamethasone for RRMM | 2027-06-30 |
| NCT03710421City of Hope Medical CenterCS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma | 2027-08-13 |
Add all 8 to your calendar (.ics) → With an account.
Among the 171 studies testing cyclophosphamide in Multiple Myeloma, from their registry updates:
Among Johnson & Johnson’s 126 in Multiple Myeloma:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety and effectiveness of bortezomib in combination with a standard regimen of cyclophosphamide and dexamethasone.
This is open-label (both the participant and the investigator know what treatment participants will receive), prospective (participants are identified and then followed forward in time for the outcome of the study), multi-centre, and non-randomized (participants are assigned to different treatment groups by the investigator) study. The study will be conducted into 2 parts (Part 1 and Part 2). Approximately 400 participants will be enrolled (30 in Part 1 and 370 in Part 2). In Part 1 the optimum dose of cyclophosphamide will be evaluated and in Part 2 the selected dose of cyclophosphamide from Part 1 will be administered. Part 2 will include a screening period of a maximum of 14 days followed by chemotherapy (bortezomib, cyclophosphamide, and dexamethasone) of a maximum of three 21-day cycles. Safety will be evaluated by the assessment of adverse events, vital signs, physical examination, electrocardiogram, and clinical laboratory tests which will be monitored throughout the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Part 1 will be the dose titration part for cyclophosphamide. Participants will receive cyclophosphamide, bortezomib, and dexamethasone for 3 cycles. In Part 2, participants will receive cyclophosphamide (dose determined in Part 1) with pre-defined dose of bortezomib and dexamethasone for 3 cycles.
Drug: Cyclophosphamide · Drug: Bortezomib · Drug: Dexamethasone
In Part 1, cyclophosphamide with dose ranging from 900 to 1500 mg will be administered intravenously on Day 1 of each 21 day cycle for 3 cycles to determine optimal dose. In Part 2, optimal dose determined in Part 1 will be administered on Day 1 of each 21 day cycle for 3 cycles.
Bortezomib 1.3 mg/m2 will be administered intravenously on Days 1,4,8, and 11 of each 21 day cycle for 3 cycles in both parts (Part 1 and Part 2).
Also known as: VELCADE
Participants will receive dexamethasone 40 mg orally or intravenously on Days 1, 2, 4, 5, 8, 9, 11, and 12 of each 21 day cycle for 3 cycles in both parts (Part 1 and Part 2).
Participants With Complete Response (CR) + Partial Response (PR) (Efficacy Set)
CR and PR are defined by the local investigator according to the current European Group for Blood and Marrow Transplantation (EBMT) criteria. According to EBMT criteria, CR is defined as the absence of serum and urine monoclonal paraprotein + no increase in size or number of lytic bone lesions; and PR is defined as not all CR criteria + 50 percentage or more reduction in serum monoclonal paraprotein.
Time frame: Up to Day 63
Participants With Complete Response (CR) + Partial Response (PR) (Per-protocol Analysis Set)
CR and PR are defined by the local investigator according to the current European Group for Blood and Marrow Transplantation (EBMT) criteria. According to EBMT criteria, CR is defined as the absence of serum and urine monoclonal paraprotein + no increase in size or number of lytic bone lesions; and PR is defined as not all CR criteria + 50 percentage or more reduction in serum monoclonal paraprotein.
Time frame: Up to Day 63
Percentage of Participants With Complete Response + Partial Response in Relation to Cytogenetic Subgroups (Efficacy Set)
Response rate was defined as the percentage of participants with response of combined CR+PR according to the EBMT criteria. As per the EBMT criteria, CR is defined as the absence of serum and urine monoclonal paraprotein and no increase in size or number of lytic bone lesions; PR is defined as not all CR criteria and 50 percentage or more reduction in serum monoclonal paraprotein. Percentage of participants with complete or partial response that carried the indicated cytogenetic marker is reported. Same participant could count in more than one category due to multiple responses possible
Time frame: Up to Day 63
Percentage of Participants With Complete Response + Partial Response in Relation to Cytogenetic Subgroups (Per-protocol Set)
Response rate was defined as the percentage of participants with response of combined CR+PR according to the EBMT criteria. As per the EBMT criteria, CR is defined as the absence of serum and urine monoclonal paraprotein and no increase in size or number of lytic bone lesions; PR is defined as not all CR criteria and 50 percentage or more reduction in serum monoclonal paraprotein. Percentage of participants with complete or partial response that carried the indicated cytogenetic marker is reported. Same participant could count in more than one category due to multiple responses possible.
Time frame: Up to Day 63
401 participants were enrolled at 41 study sites in Germany.
| Milestone | Cyclophosphamide + Bortezomib + Dexamethasone |
|---|---|
| Started | 395 |
| Completed | 353 |
| Not completed | 42 |
| Withdrew: Toxicity | 13 |
| Withdrew: Adverse event | 11 |
| Withdrew: Protocol violation | 6 |
| Withdrew: Lack of efficacy | 4 |
| Withdrew: Death | 2 |
| Withdrew: Pregression of other disease | 1 |
| Withdrew: Other | 5 |
CR and PR are defined by the local investigator according to the current European Group for Blood and Marrow Transplantation (EBMT) criteria. According to EBMT criteria, CR is defined as the absence of serum and urine monoclonal paraprotein + no increase in size or number of lytic bone lesions; and PR is defined as not all CR criteria + 50 percentage or more reduction in serum monoclonal paraprotein.
| Participants | Cyclophosphamide + Bortezomib + Dexamethasone |
|---|---|
| Participants With Complete Response (CR) + Partial Response (PR) (Efficacy Set) | 334 |
CR and PR are defined by the local investigator according to the current European Group for Blood and Marrow Transplantation (EBMT) criteria. According to EBMT criteria, CR is defined as the absence of serum and urine monoclonal paraprotein + no increase in size or number of lytic bone lesions; and PR is defined as not all CR criteria + 50 percentage or more reduction in serum monoclonal paraprotein.
| Participants | Cyclophosphamide + Bortezomib + Dexamethasone |
|---|---|
| Participants With Complete Response (CR) + Partial Response (PR) (Per-protocol Analysis Set) | 284 |
Response rate was defined as the percentage of participants with response of combined CR+PR according to the EBMT criteria. As per the EBMT criteria, CR is defined as the absence of serum and urine monoclonal paraprotein and no increase in size or number of lytic bone lesions; PR is defined as not all CR criteria and 50 percentage or more reduction in serum monoclonal paraprotein. Percentage of participants with complete or partial response that carried the indicated cytogenetic marker is reported. Same participant could count in more than one category due to multiple responses possible
| Percentage of participants | Cyclophosphamide + Bortezomib + Dexamethasone |
|---|---|
| 13q- (n=112) | 90.2 |
| t (4;14) (n=38) | 89.5 |
| 17p- (n=31) | 74.2 |
| Other (n=104) | 87.5 |
| No changes (n=102) | 84.3 |
Response rate was defined as the percentage of participants with response of combined CR+PR according to the EBMT criteria. As per the EBMT criteria, CR is defined as the absence of serum and urine monoclonal paraprotein and no increase in size or number of lytic bone lesions; PR is defined as not all CR criteria and 50 percentage or more reduction in serum monoclonal paraprotein. Percentage of participants with complete or partial response that carried the indicated cytogenetic marker is reported. Same participant could count in more than one category due to multiple responses possible.
| Percentage of participants | Cyclophosphamide + Bortezomib + Dexamethasone |
|---|---|
| 13q- (n=92) | 92.4 |
| t (4;14) (n=34) | 91.2 |
| 17p- (n=24) | 87.5 |
| Other (n=87) | 88.5 |
| No changes (n=87) | 85.1 |
Collected over From date of inform consent signed to 30 days after the last bortezomib dosing or, if earlier, until start of an alternative myeloma therapy.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cyclophosphamide + Bortezomib + Dexamethasone | — | 103/395 (26.1%) | 392/395 (99.2%) |
| Event | Cyclophosphamide + Bortezomib + Dexamethasone |
|---|---|
| PneumoniaInfections and infestations | 15/395 |
| PyrexiaGeneral disorders | 14/395 |
| LeukopeniaBlood and lymphatic system disorders | 11/395 |
| DiarrhoeaGastrointestinal disorders | 5/395 |
| NeutropeniaBlood and lymphatic system disorders | 4/395 |
| ConstipationGastrointestinal disorders | 4/395 |
| NauseaGastrointestinal disorders | 4/395 |
| PolyneuropathyNervous system disorders | 4/395 |
| Cardiac failureCardiac disorders | 4/395 |
| Herpes zosterInfections and infestations | 3/395 |
| Event | Cyclophosphamide + Bortezomib + Dexamethasone |
|---|---|
| LeukopeniaBlood and lymphatic system disorders | 211/395 |
| ThrombocytopeniaBlood and lymphatic system disorders | 129/395 |
| NauseaGastrointestinal disorders | 105/395 |
| ConstipationGastrointestinal disorders | 86/395 |
| Oedema peripheralGeneral disorders | 79/395 |
| AnaemiaBlood and lymphatic system disorders | 77/395 |
| FatigueGeneral disorders | 76/395 |
| DiarrhoeaGastrointestinal disorders | 73/395 |
| ParaesthesiaNervous system disorders | 63/395 |
| PyrexiaGeneral disorders | 56/395 |
| Age, Continuous(Years) | Cyclophosphamide + Bortezomib + Dexamethasone |
|---|---|
| Mean | 52.4 ± 6.5 |
| Age, Customized(Participants) | Cyclophosphamide + Bortezomib + Dexamethasone |
|---|---|
| Between 20 and 39 years | 17 |
| Between 40 and 49 years | 109 |
| Between 50 and 60 years | 253 |
| >65 years | 16 |
| Sex: Female, Male(Participants) | Cyclophosphamide + Bortezomib + Dexamethasone |
|---|---|
| Female | 166 |
| Male | 229 |
The record gives a start of Mar 2006, a primary completion of Jun 2009 and a completion of Jun 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2014, 4 years 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Cyclophosphamide · Bortezomib · Dexamethasone